395 related articles for article (PubMed ID: 32229606)
1. Biophysical and Immunological Characterization and
Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
[TBL] [Abstract][Full Text] [Related]
2. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
Plitnick LM; Hutchins B; Dubey S; Li N; Amin RP; Born S; Mangadu R; Phillips JH; Sriram V; Herzyk DJ
J Immunotoxicol; 2020 Dec; 17(1):175-185. PubMed ID: 33078980
[TBL] [Abstract][Full Text] [Related]
3. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
[TBL] [Abstract][Full Text] [Related]
5. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
6. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
[TBL] [Abstract][Full Text] [Related]
7. PET/CT Imaging of
Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
[TBL] [Abstract][Full Text] [Related]
8. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
9. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
Front Immunol; 2021; 12():737076. PubMed ID: 34659228
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Fu J; Wang F; Dong LH; Zhang J; Deng CL; Wang XL; Xie XY; Zhang J; Deng RX; Zhang LB; Wu H; Feng H; Chen B; Song HF
Acta Pharmacol Sin; 2017 May; 38(5):710-718. PubMed ID: 28317872
[TBL] [Abstract][Full Text] [Related]
12. In-vitro effect of pembrolizumab on different T regulatory cell subsets.
Toor SM; Syed Khaja AS; Alkurd I; Elkord E
Clin Exp Immunol; 2018 Feb; 191(2):189-197. PubMed ID: 28963773
[TBL] [Abstract][Full Text] [Related]
13. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
Commun Biol; 2019; 2():392. PubMed ID: 31667366
[TBL] [Abstract][Full Text] [Related]
14. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
McDermott J; Jimeno A
Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
De Sousa Linhares A; Battin C; Jutz S; Leitner J; Hafner C; Tobias J; Wiedermann U; Kundi M; Zlabinger GJ; Grabmeier-Pfistershammer K; Steinberger P
Sci Rep; 2019 Aug; 9(1):11472. PubMed ID: 31391510
[TBL] [Abstract][Full Text] [Related]
19. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.
DeAngelis N; Ferrante C; Powers G; Sendecki J; Mattson B; Pizutti D; Packman K; Wang W; Trouba K; Nanjunda R; Wheeler J; Brittingham R; Wu SJ; Luo J; Lorenzi MV; Verona RI
Cancer Chemother Pharmacol; 2022 Apr; 89(4):515-527. PubMed ID: 35298699
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
